Gastrointestinal and ovarian malignancies frequently recur with metastatic disease limited to the abdominal cavity. Due to full thickness penetration of
tumor through bowel wall, spillage of
tumor from lymphatic channels by surgical
trauma or perforation of the
tumor through the ovarian capsule,
tumor cells are disseminated throughout the peritoneal surfaces either prior to or at the time of surgical removal of the primary
tumor. In the past, diagnosis of recurrent
cancer was difficult because no sensitive diagnostic test was available by which to image a small
tumor volume present on peritoneal surfaces. Computerized tomography with
intraperitoneal infusion of contrast can demonstrate
tumor nodules not otherwise detectable. Intraperitoneal installation of I-131 labeled monoclonal antibody has allowed visualization of mucinous
tumor on peritoneal surfaces not seen by any other radiologic test. Intraperitoneal
chemotherapy has been shown to provide palliation in patients with small volume disease confined to peritoneal surfaces. Because of limited penetration of
chemotherapy into large
tumor nodules this treatment strategy has not been effective for bulky intraabdominal recurrent
cancer. Cytoreductive surgery utilizing high voltage
electrocautery and
CO2 laser evaporation of
tumor can make patients relatively disease free. These surgical technologies combined with postoperative intraperitoneal
chemotherapy have been shown to be of benefit for selected patients with recurrent intraabdominal
cancer. The wider application of these intraperitoneal
chemotherapy treatments for patients in an adjuvant setting may be of value in preventing the occurrence of peritoneal carcinosis and in improving survival.